Novo Nordisk A/S
NONOF
$136.48
-$1.77-1.28%
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 37.42B | 35.53B | 33.71B | 30.81B | 28.40B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 37.42B | 35.53B | 33.71B | 30.81B | 28.40B |
| Cost of Revenue | 5.79B | 5.46B | 5.19B | 4.88B | 4.44B |
| Gross Profit | 31.63B | 30.08B | 28.52B | 25.93B | 23.96B |
| SG&A Expenses | 9.16B | 9.10B | 8.94B | 8.32B | 7.98B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 9.52M | 70.15M | -17.31M | -76.35M | -70.17M |
| Total Operating Expenses | 20.22B | 19.41B | 18.62B | 17.33B | 16.12B |
| Operating Income | 17.20B | 16.13B | 15.09B | 13.48B | 12.28B |
| Income Before Tax | 16.39B | 16.28B | 15.19B | 13.45B | 11.79B |
| Income Tax Expenses | 3.34B | 3.29B | 3.05B | 2.60B | 2.28B |
| Earnings from Continuing Operations | 13.05K | 12.99K | 12.15K | 10.84K | 9.51K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 13.05B | 12.99B | 12.15B | 10.84B | 9.51B |
| EBIT | 17.20B | 16.13B | 15.09B | 13.48B | 12.28B |
| EBITDA | 18.66B | 17.45B | 16.24B | 14.59B | 13.30B |
| EPS Basic | 2.92 | 2.91 | 2.71 | 2.41 | 2.11 |
| Normalized Basic EPS | 2.44 | 2.30 | 2.15 | 1.90 | 1.66 |
| EPS Diluted | 2.91 | 2.90 | 2.70 | 2.41 | 2.11 |
| Normalized Diluted EPS | 2.43 | 2.30 | 2.14 | 1.89 | 1.66 |
| Average Basic Shares Outstanding | 17.86B | 17.89B | 17.93B | 17.97B | 18.02B |
| Average Diluted Shares Outstanding | 17.90B | 17.94B | 17.98B | 18.03B | 18.08B |
| Dividend Per Share | 1.43 | 1.36 | 1.36 | 1.00 | 1.00 |
| Payout Ratio | 46.91% | 47.10% | 37.90% | 42.45% | 41.47% |
